Not available
Quote | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
Last: | $1.50 |
---|---|
Change Percent: | -4.83% |
Open: | $1.52 |
Close: | $1.50 |
High: | $1.7 |
Low: | $1.465 |
Volume: | 4,029,824 |
Last Trade Date Time: | 06/14/2024 03:00:00 am |
News | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - - Overall Response Rate (ORR) of 33% and 50% Achieved to Date in 60 mg QW and 30 mg BIW Cohorts, Respectively - - 45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Su...
2024-05-21 17:42:10 ET More on SELLAS Life Sciences Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout Sellas reports positive Phase 2 data from AML study, files for patent SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL...
Message Board Posts | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $SLS News Article - Solaris Discovers New Porphyry Southwest of Warintza Central, with | whytestocks | investorshangout | 04/11/2023 4:30:58 PM |
After that dilution itl double in price, always does | harry crumb | investorshub | 03/03/2023 4:19:41 PM |
Breakout coming, this science could be a game changer | harry crumb | investorshub | 02/16/2023 2:23:43 AM |
Fingers crossed! Still an unknown, to us, | TTsr | investorshub | 02/03/2023 3:29:52 PM |
News coming? Its rippn | harry crumb | investorshub | 02/03/2023 3:17:11 PM |
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - - Overall Response Rate (ORR) of 33% and 50% Achieved to Date in 60 mg QW and 30 mg BIW Cohorts, Respectively - - 45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Su...
Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in ...
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - ...